Cargando…
Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung
BACKGROUND: Targeted therapies based on the molecular and histological features of cancer types are becoming standard practice. The most effective regimen in lung cancers is different between squamous cell carcinoma (SCC) and adenocarcinoma (AD). Therefore a precise diagnosis is crucial, but this ha...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041559/ https://www.ncbi.nlm.nih.gov/pubmed/27681076 http://dx.doi.org/10.1186/s12885-016-2792-1 |
_version_ | 1782456436936146944 |
---|---|
author | Takamochi, Kazuya Ohmiya, Hiroko Itoh, Masayoshi Mogushi, Kaoru Saito, Tsuyoshi Hara, Kieko Mitani, Keiko Kogo, Yasushi Yamanaka, Yasunari Kawai, Jun Hayashizaki, Yoshihide Oh, Shiaki Suzuki, Kenji Kawaji, Hideya |
author_facet | Takamochi, Kazuya Ohmiya, Hiroko Itoh, Masayoshi Mogushi, Kaoru Saito, Tsuyoshi Hara, Kieko Mitani, Keiko Kogo, Yasushi Yamanaka, Yasunari Kawai, Jun Hayashizaki, Yoshihide Oh, Shiaki Suzuki, Kenji Kawaji, Hideya |
author_sort | Takamochi, Kazuya |
collection | PubMed |
description | BACKGROUND: Targeted therapies based on the molecular and histological features of cancer types are becoming standard practice. The most effective regimen in lung cancers is different between squamous cell carcinoma (SCC) and adenocarcinoma (AD). Therefore a precise diagnosis is crucial, but this has been difficult, particularly for poorly differentiated SCC (PDSCC) and AD without a lepidic growth component (non-lepidic AD). Biomarkers enabling a precise diagnosis are therefore urgently needed. METHODS: Cap Analysis of Gene Expression (CAGE) is a method used to quantify promoter activities across the whole genome by determining the 5’ ends of capped RNA molecules with next-generation sequencing. We performed CAGE on 97 frozen tissues from surgically resected lung cancers (22 SCC and 75 AD), and confirmed the findings by immunohistochemical analysis (IHC) in an independent group (29 SCC and 45 AD). RESULTS: Using the genome-wide promoter activity profiles, we confirmed that the expression of known molecular markers used in IHC for SCC (CK5, CK6, p40 and desmoglein-3) and AD (TTF-1 and napsin A) were different between SCC and AD. We identified two novel marker candidates, SPATS2 for SCC and ST6GALNAC1 for AD, as showing comparable performance and complementary utility to the known markers in discriminating PDSCC and non-lepidic AD. We subsequently confirmed their utility at the protein level by IHC in an independent group. CONCLUSIONS: We identified two genes, SPATS2 and ST6GALNAC1, as novel complemental biomarkers discriminating SCC and AD. These findings will contribute to a more accurate diagnosis of NSCLC, which is crucial for precision medicine for lung cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2792-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5041559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50415592016-10-05 Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung Takamochi, Kazuya Ohmiya, Hiroko Itoh, Masayoshi Mogushi, Kaoru Saito, Tsuyoshi Hara, Kieko Mitani, Keiko Kogo, Yasushi Yamanaka, Yasunari Kawai, Jun Hayashizaki, Yoshihide Oh, Shiaki Suzuki, Kenji Kawaji, Hideya BMC Cancer Research Article BACKGROUND: Targeted therapies based on the molecular and histological features of cancer types are becoming standard practice. The most effective regimen in lung cancers is different between squamous cell carcinoma (SCC) and adenocarcinoma (AD). Therefore a precise diagnosis is crucial, but this has been difficult, particularly for poorly differentiated SCC (PDSCC) and AD without a lepidic growth component (non-lepidic AD). Biomarkers enabling a precise diagnosis are therefore urgently needed. METHODS: Cap Analysis of Gene Expression (CAGE) is a method used to quantify promoter activities across the whole genome by determining the 5’ ends of capped RNA molecules with next-generation sequencing. We performed CAGE on 97 frozen tissues from surgically resected lung cancers (22 SCC and 75 AD), and confirmed the findings by immunohistochemical analysis (IHC) in an independent group (29 SCC and 45 AD). RESULTS: Using the genome-wide promoter activity profiles, we confirmed that the expression of known molecular markers used in IHC for SCC (CK5, CK6, p40 and desmoglein-3) and AD (TTF-1 and napsin A) were different between SCC and AD. We identified two novel marker candidates, SPATS2 for SCC and ST6GALNAC1 for AD, as showing comparable performance and complementary utility to the known markers in discriminating PDSCC and non-lepidic AD. We subsequently confirmed their utility at the protein level by IHC in an independent group. CONCLUSIONS: We identified two genes, SPATS2 and ST6GALNAC1, as novel complemental biomarkers discriminating SCC and AD. These findings will contribute to a more accurate diagnosis of NSCLC, which is crucial for precision medicine for lung cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2792-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-29 /pmc/articles/PMC5041559/ /pubmed/27681076 http://dx.doi.org/10.1186/s12885-016-2792-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Takamochi, Kazuya Ohmiya, Hiroko Itoh, Masayoshi Mogushi, Kaoru Saito, Tsuyoshi Hara, Kieko Mitani, Keiko Kogo, Yasushi Yamanaka, Yasunari Kawai, Jun Hayashizaki, Yoshihide Oh, Shiaki Suzuki, Kenji Kawaji, Hideya Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title | Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title_full | Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title_fullStr | Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title_full_unstemmed | Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title_short | Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
title_sort | novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041559/ https://www.ncbi.nlm.nih.gov/pubmed/27681076 http://dx.doi.org/10.1186/s12885-016-2792-1 |
work_keys_str_mv | AT takamochikazuya novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT ohmiyahiroko novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT itohmasayoshi novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT mogushikaoru novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT saitotsuyoshi novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT harakieko novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT mitanikeiko novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT kogoyasushi novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT yamanakayasunari novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT kawaijun novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT hayashizakiyoshihide novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT ohshiaki novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT suzukikenji novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung AT kawajihideya novelbiomarkersthatassistinaccuratediscriminationofsquamouscellcarcinomafromadenocarcinomaofthelung |